Publications by authors named "Y Aisaka"
Introduction: Systemic therapy is recommended for patients with Child-Pugh A in hepatocellular carcinoma (HCC). We analyzed the outcomes of a cohort of patients with HCC who received either sorafenib (Sor), lenvatinib (Len) or atezolizumab plus bevacizumab (Atezo + Bev) as first-line systemic therapy for HCC, with the aim of identifying prognostic factors for survival.
Methods: A total of 825 patients with advanced HCC and Child-Pugh A or B received either Sor, Len or Atezo + Bev as first-line systemic therapy.
Article Synopsis
- Transarterial chemoembolization (TACE) has traditionally been the go-to treatment for intermediate-stage, unresectable hepatocellular carcinoma (u-HCC), but new studies show systemic therapy can be effective for patients considered TACE-refractory or -unsuitable.
- A study involving 140 patients evaluated the effectiveness of the drug lenvatinib, finding median overall survival of 24.4 months and progression-free survival of 9.0 months, suggesting a good response to treatment.
- The research highlights the importance of using systemic therapy in TACE-refractory patients and indicates that combining TACE after initiating lenvatinib can enhance patient outcomes.
Article Synopsis
- - The study looked at how well radiological responses to lenvatinib treatment predicted overall survival (OS) in 182 patients with advanced liver cancer, using specific evaluation criteria.
- - Results showed that a favorable initial radiological response was linked to longer OS and served as an important independent predictor of survival outcomes.
- - In cases where patients had stable disease at first evaluation, assessments like macrovascular invasion and liver function scores could help decide whether to continue or change treatment strategies.
Introduction: This study compared clinical outcomes of 2nd- and 3rd-line regorafenib in patients with unresectable hepatocellular carcinoma.
Methods: In this retrospective cohort study, 48 patients were treated with regorafenib for unresectable hepatocellular carcinoma. Thirty-five and 13 patients were initiated on 2nd- and 3rd-line therapy, respectively.
Introduction: We evaluated the efficacy and safety of lenvatinib-transcatheter arterial chemoembolization (LEN-TACE) sequential therapy for patients (n = 88) with intermediate-stage hepatocellular carcinoma (HCC).
Methods: Eighty-eight patients who obtained tumor control by LEN treatment were analyzed; 30 received LEN followed by TACE (LEN-TACE sequential therapy), and 58 received LEN monotherapy. Propensity score matching was performed, and the outcomes of 19 patients in the LEN-TACE group and 19 patients in the LEN-alone group were compared.